HF
XLO icon

HRT Financial’s Xilio Therapeutics XLO Stock Holding History

HRT Financial’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,278
Closed -$20K – 4871
2025
Q4 		$20K Buy
2,278
+511
+29% +$5.37K ﹤0.01% 2983
2025
Q3 		$20K Buy
+1,767
New +$17.7K ﹤0.01% 2704

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

HRT Financial's XLO Position: Q1 2026 in Review

HRT Financial sold out of Xilio Therapeutics (XLO) in Q1 2026, closing a stake of 2,278 shares — an estimated $20K sold.

HRT Financial first reported a position in XLO in Q3 2025 and held it in 2 quarters. The position peaked at $20K in Q4 2025. 24 funds tracked by Wall St. Rank hold XLO as of Q1 2026.

  • HRT Financial reported no remaining Xilio Therapeutics position as of Q1 2026 after selling out during the quarter.
  • HRT Financial sold 2,278 Xilio Therapeutics shares in Q1 2026, an estimated $20K.
  • HRT Financial first reported a position in Xilio Therapeutics in Q3 2025 and held it in 2 quarters.
  • HRT Financial's Xilio Therapeutics position peaked at $20K in Q4 2025.
  • 24 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.